Loading clinical trials...
Loading clinical trials...
A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDE225 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.
Conditions
Interventions
LDE225
Locations
5
United States
University of Miami Div. of Clinical Pharmacology
Miami, Florida, United States
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Tel Aviv, Israel
Start Date
March 1, 2013
Primary Completion Date
March 1, 2015
Completion Date
March 1, 2015
Last Updated
December 19, 2020
NCT07055412
NCT02586194
NCT00398424
NCT04823702
NCT04136444
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions